"FDA Approves Iovance's Groundbreaking Cell Therapy for Advanced Melanoma"
TL;DR Summary
The FDA has granted accelerated approval to Iovance Biotherapeutics for their cell therapy, Amtagvi, designed for patients with advanced melanoma. This marks the first modern cell therapy for a solid tumor, as well as the first approved treatment based on tumor-infiltrating lymphocytes (TILs), representing a significant milestone in cancer treatment after more than 40 years of development.
Topics:business#cell-therapy#fda#healthcare#iovance-biotherapeutics#melanoma#tumor-infiltrating-lymphocytes
- FDA approves Iovance's cell therapy for melanoma, the first treatment based on tumor-infiltrating lymphocytes Endpoints News
- FDA approves new therapy for hard-to-treat metastatic melanoma CNN
- FDA approves groundbreaking treatment for advanced melanoma NBC News
- Iovance Biotherapeutics to Host Conference Call and Webcast on Friday, February 16, 2024 Yahoo Finance
- In 'major milestone,' FDA approves first cell therapy for solid tumors STAT
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
0 min
vs 1 min read
Condensed
43%
100 → 57 words
Want the full story? Read the original article
Read on Endpoints News